Cargando…

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia

BACKGROUND: Astrocytes play an essential role in neuroinflammation and are involved in the pathogenesis of neurodenegerative diseases. Studies of glial fibrillary acidic protein (GFAP), an astrocytic damage marker, may help advance our understanding of different neurodegenerative diseases. In this s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Nuole, Santos-Santos, Miguel, Illán-Gala, Ignacio, Montal, Victor, Estellés, Teresa, Barroeta, Isabel, Altuna, Miren, Arranz, Javier, Muñoz, Laia, Belbin, Olivia, Sala, Isabel, Sánchez-Saudinós, Maria Belén, Subirana, Andrea, Videla, Laura, Pegueroles, Jordi, Blesa, Rafael, Clarimón, Jordi, Carmona-Iragui, Maria, Fortea, Juan, Lleó, Alberto, Alcolea, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662866/ https://www.ncbi.nlm.nih.gov/pubmed/34893073 http://dx.doi.org/10.1186/s40035-021-00275-w

Ejemplares similares

Correction: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia
por: Zhu, Nuole, et al.
Publicado: (2023)

The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone
por: Delaby, Constance, et al.
Publicado: (2022)

Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer’s disease-related inhibitory circuit dysfunction in adults with Down syndrome
por: Belbin, Olivia, et al.
Publicado: (2020)

Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders
por: Delaby, C., et al.
Publicado: (2020)

Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease
por: Jimenez, Amanda, et al.
Publicado: (2017)

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study
por: Fortea, Juan, et al.
Publicado: (2020)

Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down Syndrome
por: Videla, Laura, et al.
Publicado: (2022)

VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study
por: Pegueroles, Jordi, et al.
Publicado: (2018)

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome
por: Lleó, Alberto, et al.
Publicado: (2021)

Neural correlates of episodic memory in adults with Down syndrome and Alzheimer’s disease
por: Benejam, Bessy, et al.
Publicado: (2022)

Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome
por: Bejanin, Alexandre, et al.
Publicado: (2021)

Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly
por: Pegueroles, Jordi, et al.
Publicado: (2020)

The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders
por: Alcolea, Daniel, et al.
Publicado: (2019)

Association of biological sex with clinical outcomes and biomarkers of Alzheimer’s disease in adults with Down syndrome
por: Iulita, M Florencia, et al.
Publicado: (2023)

APP‐derived peptides reflect neurodegeneration in frontotemporal dementia
por: Illán‐Gala, Ignacio, et al.
Publicado: (2019)

APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls
por: Sampedro, Frederic, et al.
Publicado: (2015)

Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome
por: Iulita, Maria Florencia, et al.
Publicado: (2022)

Challenges associated with biomarker-based classification systems for Alzheimer's disease
por: Illán-Gala, Ignacio, et al.
Publicado: (2018)

Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests
por: Benejam, Bessy, et al.
Publicado: (2020)

AMYQ: An index to standardize quantitative amyloid load across PET tracers
por: Pegueroles, Jordi, et al.
Publicado: (2021)

Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis
por: Dols-Icardo, Oriol, et al.
Publicado: (2020)

YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer’s disease and other tauopathies
por: Querol-Vilaseca, Marta, et al.
Publicado: (2017)

Evaluation of biochemical and hematological parameters in adults with Down syndrome
por: de Gonzalo-Calvo, David, et al.
Publicado: (2020)

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
por: Alcolea, Daniel, et al.
Publicado: (2019)

Cortical microstructure in primary progressive aphasia: a multicenter study
por: Illán-Gala, Ignacio, et al.
Publicado: (2022)

Correction: Cortical microstructure in primary progressive aphasia: a multicenter study
por: Illán-Gala, Ignacio, et al.
Publicado: (2023)

Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer’s disease
por: Morenas-Rodríguez, Estrella, et al.
Publicado: (2019)

Feasibility and Long-Term Compliance to Continuous Positive Airway Pressure Treatment in Adults With Down Syndrome, a Genetic Form of Alzheimer’s Disease
por: Giménez, Sandra, et al.
Publicado: (2022)

DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients
por: Moreau, Manon, et al.
Publicado: (2022)

Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies
por: Reyes-Leiva, David, et al.
Publicado: (2022)

Mechanisms Involved in Epileptogenesis in Alzheimer’s Disease and Their Therapeutic Implications
por: Altuna, Miren, et al.
Publicado: (2022)

Nanoscale structure of amyloid-β plaques in Alzheimer’s disease
por: Querol-Vilaseca, Marta, et al.
Publicado: (2019)

Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study
por: Pentz, Rowan, et al.
Publicado: (2020)

Cognitive symptoms after COVID-19
por: Altuna, M., et al.
Publicado: (2021)

Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum
por: Goossens, Julie, et al.
Publicado: (2023)

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease
por: Dekker, Alain D., et al.
Publicado: (2017)

Epilepsy in Down Syndrome: A Highly Prevalent Comorbidity
por: Altuna, Miren, et al.
Publicado: (2021)

Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration
por: Cervantes González, Alba, et al.
Publicado: (2022)

Downregulation of miR-335-5P in Amyotrophic Lateral Sclerosis Can Contribute to Neuronal Mitochondrial Dysfunction and Apoptosis
por: De Luna, Noemi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mgtqkt18629fr3l36pfp00utfd